Market Overview

Anti-Her2 Antibody-Drug Conjugates in 2016: R&D and Business Tracker for Antibody-Drug Conjugates - Research and Markets


Research and Markets has announced the addition of the "Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates" report to their offering.

This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.

The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:

R&D and Technology Tracker:

- Pipeline changes

- Regulatory news

- Technology validations

- Manufacturing news

Business Tracker for:

- Company updates

- Collaboration

- Licensing

- Merger & acquisitions

- Financing

Clinical Trial Tracker:

- Scientific Publication Tracker

- Featured ADC Profile: MEDI4276

- Featured Company Profile: NBE Therapeutics

- Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates

Information about the anti-Her2 ADC pipeline is provided in a tabular format and fully referenced.

For more information about this report visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs , Oncology Drugs

View Comments and Join the Discussion!